Sanofi-Aventis & Regeneron v Amgen (UPC_CoA_528/2024 UPC_CoA_529/2024 N/A UPC_CoA_528/2024 UPC_CoA_529/2024)

Decision date:

25 March 2026

Court

Court of Appeal

Patent

EP 3 666 797

Full decision available here:

Osborne Clarke summary

Sanofi and Regeneron brought revocation proceedings against Amgen’s patent in issue before the Munich CD. The Munich CD revoked the patent; however, the Court of Appeal overturned that decision. Sanofi and Regeneron applied for a rehearing. Later, Sanofi and Regeneron sought to withdraw their application for a rehearing, which Amgen consented to, and applied for reimbursement of 50% of the court fees. The Court of Appeal permitted the withdrawal of the application, but made no decision on costs as none of the parties requested it. The court rejected Sanofi and Regeneron’s application for reimbursement of court fees as there was no reason for reimbursement under Rule 370.9(b) RoP.

Reach out to our patents team for expert guidance and support.